Intersect ENT (NASDAQ:XENT) Rating Reconfirmed
In a research report issued to investors and clients on today, Wedbush kept their Outperform rating on Intersect Ent (NASDAQ:XENT)’s stock. The TP suggests a potential upside of 29.68 % from firm’s last price.
NASDAQ:XENT is currently trading 0.50% higher at $20.05 as of 12:01 AM New York time. Intersect ENT’s stock is 0% over the past 200 days. It has underperformed the S&P 500, which has increased 10.61% over the same time.
According to data compiled by Thomson Reuters, Intersect ENT (NASDAQ:XENT)’s stock is covered by 7 equity analysts across the Street, with 0 analysts giving it a Sell rating, 8 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $25.14, which reflects an upside potential of 25.39% over the current price.
Intersect ENT (NASDAQ:XENT) Profile
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents.
Intersect ENT (NASDAQ:XENT) traded up 0.50% on 3 May, hitting $20.05. A total of shares of the company’s stock traded hands. This is down from average of 234,942 shares. Intersect ENT has a 52 week low of $7.65 and a 52 week high of $20.64. The company has a market cap of $605.44M and a P/E ratio of 0.
Get the latest Intersect ENT (NASDAQ:XENT) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Wedbush Analyst Reaffirmed $26.0 Price Target on Intersect ENT (NASDAQ:XENT) stock, While Reiterating Outperform Rating appeared first on Octafinance.